Zhejiang medicine "counterattacks" the U.S. successfully, and the whole country's API is equivalent to getting tariff exemption

Recently, according to official wechat of Zhejiang Shaoxing Bureau of Commerce, Zhejiang Pharmaceutical actively defended by participating in the U.S hearing, the export products of fine chemicals, APIs and preparations in China were finally excluded from the list of US $34 billion commodity plus 25% tariff Therefore, a lot of multimedia reports were made, and the relevant person in charge of Zhejiang Pharmaceutical confirmed the truth of the news At the beginning of April this year, the USTR released a list of Chinese goods to be taxed according to the results of "301 investigation" President trump announced that it would impose tariffs on about $50 billion of Chinese imports, including fine chemical APIs and preparations produced by Zhejiang medicine After the list is published, it will enter the period of public opinion and consultation, lasting for about two months The office of the trade representative said a public hearing on the tariff measure was scheduled for May 15 before a "final decision" list of products to be taxed was released Zhejiang Pharmaceutical said that as a large-scale joint-stock comprehensive pharmaceutical enterprise established in 1997, the products exported to the United States account for about 30% of the overseas sales Most of the export products win by price advantage, with a small profit If 25% extra tariff is imposed on the products, they will lose competitiveness completely, and then the market will be occupied by European or Indian manufacturers Then, Zhejiang Pharmaceutical organization participated in the U.S hearing Zhao Junxing, chief scientist of Zhejiang Pharmaceutical and vice chairman of Zhejiang innovation biology Co., Ltd (Zhejiang Pharmaceutical holding subsidiary), attended the meeting to argue that "the trade representative office just selected these commodities with advanced algorithm, but I asked the trade representative office to add some human feelings in the selection process." I told U.S officials at the hearing Zhao Junxing is a Chinese American He realized from the beginning that he should use American logic and thinking to solve problems He first found a law firm in the United States and began to sort out the evidence with strong logic He learned that the most concerned issue in the United States is the "Opium crisis" Trump announced in 2017 that the country has entered the "emergency state" of opiate abuse For this reason, he also established a special committee to combat drug addiction and opium crisis Zhao Junxing pointed out in the hearing that China Play an important role in this crisis Because the standard treatment of infected drug users in the United States is to use vancomycin, the most critical drug for patients is a "super antibiotic" that is resistant to drug-resistant bacteria, but it is no longer produced in the United States, but directly imported from China, and the vancomycin produced by Zhejiang medicine accounts for 50% of the global production (according to According to the 2017 annual report of Zhejiang Pharmaceutical, during the reporting period, the output and sales volume of vancomycin hydrochloride APIs of the company were 32 tons, most of which were sold directly to the outside world, and some of them were used to produce vancomycin hydrochloride for injection Zhao Junxing said that if the United States imposes tariffs on Chinese products, it can only import from India, the second largest source country In fact, Indian manufacturers have been purchased by China and raw materials are purchased in China, and tariffs cannot punish China Zhao Junxing also stressed that the root causes of 301 investigation are "infringement of intellectual property rights" and "Industrial Subsidy Policy of the Chinese government" According to this statement, if the two points are met, the tariff will be added Vancomycin in Zhejiang medicine does not infringe intellectual property rights, does not dump at a low price, does not enjoy government subsidies, and the product is produced according to the standard cGMP, and has full independent property rights, which is the same as the target of the United States No match It is understood that the hearing of Zhejiang Pharmaceutical Institute is the last afternoon of the three-day hearing After listening to the previous speech, Zhao Junxing found that most of the speakers of the affected enterprises did not understand the specific situation of the enterprise, and the testimony at the hearing was very macro Based on the same price, he discussed that price increase and cost increase would have an impact on them and American consumers 。 While Zhao Junxing is familiar with the process and characteristics of the U.S hearings, and he takes a new approach in the elaboration Instead of emphasizing the most obvious thing, he emphasizes the groups who are hurt behind them -- in case of drug shortage caused by tariffs, the most vulnerable groups will be hurt, such as the relationship between the supply of compound artemether and the U.S military After discovering that the deputy director of the U.S trade representative office was a lawyer of the U.S military, Zhao Jun Xing then adjusted part of the testimony at the hearing to elaborate on the cooperation between CME and the US military "The cure rate of compound artemether for malaria is higher than 96% Especially in areas where parasites have become resistant to chloroquine, a malaria drug, such as South America and Africa Therefore, we sell 1 million pieces of compound artemether to the U.S military every year Zhejiang bio innovation is the only FDA approved raw material supplier of the drug, but it is not from the so-called market distortion, but because the active ingredient in artemether is a Chinese herbal medicine After the WHO prequalification, the compound artemether is the only one available for large-scale public procurement High efficiency antimalarial drugs purchased " "At a time of trade disputes between the two countries, it is wrong to treat malaria patients and victims of opioid abuse in such a way," Zhao said in the end Therefore, I request that these two drugs be exempted from customs duties " After soliciting opinions and holding hearings, the United States conducted a comprehensive investigation and finally agreed to remove all drugs imported from China from the 301 tax catalogue, including the most critical APIs and pharmaceutical products It is understood that in April this year, Lianya pharmaceutical industry also received a tariff warning issued by the US side, including contraceptives and related pharmaceutical preparations entering the us from China Through the mediation of many parties, as the only Chinese pharmaceutical preparation Enterprise Participating in the USTR hearing, Lianya pharmaceutical has made great contributions Song Qinghui, an economist, believes that the above-mentioned enterprises' efforts to step out of the country convey a positive signal to other domestic enterprises, which is of reference significance for Chinese enterprises to "go out" They should "stand up" at the same time of "going out" In the face of unfair treatment, they should actively resist or respond to lawsuits If they can bear to admit defeat, they will only defeat themselves In addition, Zhejiang medicine has recently returned to the United States to prepare for the second round of defense, because just last month, the United States announced that it plans to impose import tariffs on 200 billion US dollars of Chinese goods, which also affected some products of its enterprises Zhao Junxing still took part in the defense, he said: "there is another hard battle to fight, we will continue to actively fight, actively defend, and have confidence to fight again We won tariff exemption After all, we have had a successful experience! "